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Modeling and analysis of positron emission tomography (PET) imaging data 
requires the critical information of the input function of the radioligand used. In PET 
imaging of the brain, the ‘gold standard’ for acquiring input function is to estimate 
the metabolite corrected arterial plasma input of the used radioligand as a function 
of time via arterial cannulation, i.e. to use the so-called original arterial input 
function (OAIF) method. Arterial cannulation, however, is unpleasant for the 
patient, invasive, requires expertise and additional resources. Consequently, it 
discourages patients and healthy subjects to enroll into clinical PET studies. To 
counter these problems, the feasibility of an alternative method for acquiring input 
function from the PET image, image-derived input function (IDIF), was evaluated for 
brain PET imaging with [11C]TMSX radioligand in this thesis. [11C]TMSX is a 
radioligand binding selectively to adenosine A2A-receptors. The method was 
implemented on data from 45 study subjects (9 healthy controls, 19 Parkinson’s 
disease patients and 17 multiple sclerosis patients) imaged with [11C]TMSX and 
High Resolution Research Tomograph (HRRT) PET scanner in earlier studies in 
Turku PET Centre. The results showed significant differences between the level of 
IDIF and OAIF values although with a high correlation. Image derived input function 
acquisition method that was used in this study is therefore not reliable enough to 
substitute original arterial input function.  Alternative IDIF extraction methods 
should be investigated for this purpose in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEYWORDS: Positron emission tomography, input function, [11C]TMSX, Multiple 
Sclerosis, Parkinson’s Disease 
  iii 
 
 
 
 
 
 
 
To my father, a man with an impeccable character and relentless courage.  
  iv 
ABBREVIATIONS 
 
18F-FDG              18F-flurodeoxyglucose 
AD                       autosomal-dominant 
AR                       autosomal-recessive  
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BBB                    blood-brain barrier 
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cAMP                  cyclic adenosine monophosphate 
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DM                      diabetes mellitus  
EAE                    experimental autoimmune encephalitis 
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MRI                     magnetic resonance imaging 
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MTR                    magnetization transfer ratio 
NAWM               normal-appearing white matter 
OAIF                   original arterial input function 
OPD                    out-patient department 
PBIF                    population based input function 
PDEA                  early stage Parkinson’s disease 
PDLN                  late stage Parkinson’s disease (non-dyskinetic) 
PET                     positron emission tomography  
PPAR-γ               peroxisome proliferator-activated receptor gamma  
PTAC                  plasma time activity curve 
RF                       radiofrequency 
ROI                     region of interest 
RRMS                 relapsing remitting multiple sclerosis 
SNARE               soluble NSF attachment protein receptor 
SNc                     substantia nigra pars compacta 
SPMS                  secondary progressive multiple sclerosis 
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1 INTRODUCTION 
 [11C]TMSX([7-methyl-11C]-(E)-8-(3,4,5-Trimethoxystyryl)1,3,7trimethylxanthine is a 
radioligand that is highly selective for A2A receptors (A2AR) in the brain. A2AR binding 
increases significantly during neuronal inflammation and therefore, is an effective marker 
for diseases such as secondary progressive multiple sclerosis (Rissanen et al., 2013a).  
 
However, before learning further about the role of A2A R’s in the pathogenesis of these 
neuronal diseases, it is important to analyze the radioligand that is being used to study it. 
There are certain pre-requisites for modeling and analysis of radioligands, the major of 
them being the input function. The ‘gold standard’ for acquiring input function is to 
estimate the metabolite corrected arterial plasma input of the used radioligand as a 
function of time via blood sampling through arterial cannulation which is distressing for 
the patients and exposes the researchers to unwarranted radiation (Litton, 1997; Zanotti-
Fregonara et al., 2011b). In order to avoid these adverse effects, we investigated an 
alternative approach for acquiring input function from the dynamic brain [11C]TMSX 
PET image data co-registered with MRI. 
  
In essence, there are three important steps that are common to all methods of acquiring 
image derived input function: (1) carotid region of interest (ROI) drawing, which can be 
done by using co-registered MRI images or segmenting the carotids directly on the PET 
images. We used the former approach in our study. (2) Partial volume effects correction 
which is then used for whole blood time activity curve (TAC) calculation. (3) Distinction 
of parent radiotracer from its metabolites by metabolite correction. This third step 
requires accurate metabolite analyses and radioactivity measurements as a function of 
time acquired via blood sampling as the PET scanner cannot distinguish between the 
original tracer and its radioactive metabolites,  
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2 LITERATURE REVIEW 
 
2.1 Multiple Sclerosis 
 
Multiple sclerosis is a chronic neuroinflammatory disease which affects, primarily, the 
long nerve axons resulting in their demyelination that may lead to significant disability. 
Around 2.5 million people are affected by this disease globally with Northern Europe and 
Canada having the highest incidence in the world. The disease typically affects young 
adults and is twice as common in females as compared to males (MS International 
Federation, 2013). 
 
In majority of the cases, the disease initially presents as relapsing remitting (RRMS) type 
of disease. The average onset of the disease is in the early thirties. With time, the disease 
gradually progresses into the secondary progressive disease (SPMS) in most patients 
within one or two decades. The symptoms of MS are varying depending on the anatomical 
location of the lesion in the CNS and may include visual impairment due to optic neuritis, 
sensory and motor symptoms, balance impairment, bladder dysfunction and cognitive 
deficits such as impairment in executive functioning and long term memory (Compston 
and Coles, 2008). As the disease progresses, the symptoms progress and accumulate 
resulting in an increasing disability and impaired quality of life (Menon et al., 2017). 
 
RRMS first manifests as episodes of neurological dysfunction called relapses. In case the 
diagnostic criteria are not met at the time of the first relapse, the condition is called  
clinically isolated syndrome. The relapses are followed by a complete or partial remission 
of the symptoms, hence the term relapsing-remitting (Barnett and Prineas, 2004). 
 
Approximately 10 percent of patients with MS are diagnosed as having primary 
progressive disease (PPMS) in which the initial symptoms keep on accumulating right 
from the disease onset. Other less common variants of MS include Balo’s concentric 
sclerosis and Marburg (or tumefactive) MS (Compston and Coles, 2008).  
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2.1.1 Pathogenesis of MS 
 
The exact cause of MS is still unclear although there is a consensus that it is a combination 
of genetic factors and yet unidentified environmental triggers that lead to disease onset in 
susceptible individuals. In genome wide associated studies (GWAS), more or less 100 
genetic sites have been identified to be a potential risk factor for developing MS 
(Beecham et al., 2013).   
 
CNS differs immunologically from the rest of the body as the blood brain barrier (BBB), 
the tight endothelial barrier between brain vasculature and brain parenchyma and 
interstitial tissue, restrict the free movement of leukocytes and large molecules from the 
blood into the CNS. 
 
MS is characterized by the inflammatory lesions, or plaques, located at the site of BBB 
breakdown due to autoimmune activity. The lesions in the early stages of the disease are 
thought to result from the presence of autoreactive T-cells, that react with specific 
autoantigens of the normal brain. These autoantigens include myelin basic protein, myelin 
oligodendrocyte glycoprotein and others. They are recognized by autoreactive CD 4+ cells 
in both normal and the disease population and it is hard to pin point which of these 
antigens are mainly responsible for the disease. 
 
CD 8+ T-cells are typically found in larger numbers in the demyelinating lesions as 
compared to CD 4+ T-cells. Their overall numbers also closely mimic the actual axonal 
damage (Frischer et al., 2009). Post-mortem brain samples of patients with SPMS often 
show significant increase of the tertiary lymphoid structures in the meninges (Howell et 
al., 2011), which is considered hallmark for chronic inflammation (Drayton et al., 2006). 
Recent studies have shown increase in leptomeningeal inflammation in PPMS (Choi et 
al., 2012). Studies have also shown a decrease in the regulatory T-cells in CSF in MS 
patients (Feger et al., 2007).  The cause of this decrease is considered to be the reduction 
in naive regulatory T-cells in addition to compensatory yet ineffective increase in the 
population of memory T-cells (Viglietta et al., 2004).  The decrease in effector-regulatory 
cell interaction helps promote autoreactive cells that ultimately leads to CNS damage. 
 
Environmental factors may play a significant role in triggering the emergence of 
autoreactive T-cells. These factors may include viruses or other microbial organisms that, 
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according to molecular mimicry hypotheses, will resemble certain myelin-related 
antigens and may then give rise to the production of auto-reactive T-cells which will 
attack the myelin within the CNS (Olson et al., 2001; Harkiolaki et al., 2009). According 
to some in-vitro studies, these microbial organisms initiate the production of toll-like 
receptors which in turn increase the production of IL 12 and IL 23 resulting in the 
production of auto-reactive T-cells (Waldner et al., 2004). Some environmental factors 
may indirectly decrease the threshold for auto-reactivity by increasing the pro-
inflammatory elements. In some instances, peripheral inflammation can contribute to 
CNS inflammation via increased production of cytokines. These cytokines are actively 
transported into the CNS through the BBB and can activate perivascular macrophages 
and microglia and this will contribute to the initiation of inflammation (Dantzer et al., 
2008).  
 
Regardless of the initiating event, inflammation resulting in new white matter lesions is 
considered as the hallmark of RRMS (Coles et al., 2006). As mentioned before, it results 
from the introduction of cytokines and chemokines in the brain which is a direct 
consequence of BBB disruption. Recent study suggests that Adenosine receptor 
manipulation could potentially help curb the entrance of inflammatory cells to the brain 
through BBB thus helping in restricting the resultant inflammatory cascade (Bynoe et al., 
2015; Carman et al., 2011). Additionally, A2A receptor stimulation may help reduce 
inflammation by decreasing cytokine production (Vincenzi et al., 2013). The pathology 
is restricted to the new focal white matter lesions in RRMS and there is little to no disease 
activity in the cortex or normal appearing white matter (NAWM). Brain atrophy has been 
noted however during RRMS which may be related to the fatigue experienced by patients 
during the early stages of the disease (Chard et al., 2002; Marrie et al., 2005).  
 
In SPMS and PMS, in contrast to RRMS, the balance tilts from inflammation towards 
neurodegeneration. There is a decrease in the number of new lesions, expansion of older 
lesions, atrophic changes in grey and white matter as well as changes in the NAWM 
(Frischer et al., 2009; Prineas et al., 2001). It has been concluded that the inflammatory 
infiltrates that result in the demyelinatory plaques along with grey and white matter 
changes are derived locally from brain connective tissues and meninges instead of the 
peripheral tissue because of a lack of observable BBB breakdown in MRI studies 
(Hochmeister et al., 2006; Choi et al., 2012; Howell et al., 2015). Activated microglia are 
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strongly linked with demyelination along with neurodegeneration observed in SPMS and 
PMS (Bø et al., 2003; Airas et al., 2015).  
 
As previously discussed, inflammation, gliosis, axonal loss along with microglial 
activation results in diffuse injury in NAWM as well as in cortical grey matter (Allen et 
al., 2001). This may also be associated with ventricular dilatation as a consequence of 
atrophic changes in the brain. Severity of NAWM injury increases as the disease 
progresses and has a correlation with the degree of cortical demyelination (Kutzelnigg et 
al., 2005; Mistry et al., 2014; Haider et al., 2014).  
 
Axonal injury in progressive MS may lead to axonal destruction, chronic demyelination 
or restorative re-myelination. Axonal destruction results from the loss of neuronal trophic 
support from other neurons. It may also result from the loss of synaptic input which leads 
to an increase in the local inflammatory response leading to neuronal degeneration 
(Banati et al., 2000).  Chronic demyelination, in-addition to losing the essential trophic 
support also cause the migration of Na+ channels from the nodes of Ranvier to the 
demyelinated segment. This leads to an increase of Na+ which is consequently 
improperly balanced by Na+ K+ dependent ATPase because of mitochondrial 
dysfunction. Increased Na+ load results in Na+ Ca2+ antiporter reversal leading to 
increased Ca2+. This results in an increase of calcium dependent enzymes leading to 
neurolysis (Franklin et al., 2012; Ransohoff, 2016). 
 
Among the multitude of factors that can increase the risk for developing MS particularly 
smoking and infectious mononucleosis caused by the Epstein-Barr virus (EBV) are 
factors that show strong association in promoting MS development (Belbasis et al., 2015). 
Circadian disruption and vitamin D deficiency may also be among the risk factors for MS 
(Hedstrom et al., 2011).   
 
Increased level of EBV antibodies and a history of infectious mononucleosis strongly 
correlates to higher risk of MS (Handel et al., 2010). Studies have postulated several 
mechanisms for EBV associated MS. It has been suggested that MS may be caused via 
reactivation of latent EBV infection that leads to activation of effector T-cells (Lossius et 
al., 2014). In addition to that, chronic viral infection may also result in higher amount of 
EBV associated memory T-cells which is significantly more noticeable in MS, and 
especially RRMS (Duszczyszyn et al., 2010). Another possible mechanism is a general 
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immune system dysregulation by EBV which may ultimately cause MS (Münz et al., 
2009).  
 
2.1.2 Signs and Symptoms of MS 
 
MS can present with variable symptoms. According to MS International Federation, 2013 
report, patients most commonly present with sensory and motor symptoms. These may 
include paresthesia, extremity weakness, diplopia, urinary retention or vertigo. Many 
patients present with painful extra-ocular movements, double vision or loss/reduction in 
vision usually caused by optic neuritis, another common finding. Some patients may 
complain about altered sensation in the back when bending the neck anteriorly, also 
known as the Lhermitte’s symptom (Multiple sclerosis in adults: management | 1-
recommendations | Guidance and guidelines | NICE).  
 
In the majority of cases the symptoms disappear after a few days or weeks followed by 
remission as described earlier. Multiple factors may enhance or reduce the severity of 
symptoms or relapses. Infections are known to exacerbate symptoms while pregnancy is 
known to reduce or eliminate relapses completely. In stark contrast, the postpartum period 
may enhance the likelihood of relapses possibly because of the alterations in the function 
of the immune system taking place after the delivery and due to the increased demands 
and stresses associated with that period (Papadakis et al., 2017).  
 
2.1.3 Diagnosis of MS 
 
Diagnosis of MS is often difficult and almost never straightforward because of a lack of 
a single confirmatory test. The signs and symptoms of MS can be caused by multiple 
diseases and therefore it is imperative that the diagnosis is done carefully and other 
potential causes are ruled out that may present in the same manner.  
 
To help facilitate the diagnosis of MS, certain pre-requisites have been set which are more 
formally known as the McDonald Criteria. The ‘gold standard’ for the diagnosis of MS 
is magnetic resonance imaging (MRI) with cerebrospinal fluid analysis  used as a support 
to rule out an alternative condition. According to the revised 2017 McDonald criteria, the 
MRI pre-requisites for diagnosis are subdivided based on the location or timing of the 
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lesion i.e. according to dissemination in space (DIS) and dissemination in time (DIT) 
respectively (Thompson et al., 2018). 
 
MRI criteria for DIS states that there should be at least one T2 lesion in 2 to 4 areas of 
the brain in order to be diagnosed as MS.  Areas that are considered as the possible sites 
for these preliminary lesions include periventricular, spinal cord, juxta cortical and 
infratemporal areas of the brain.  
 
One of the newer studies confirms earlier research that in a patient with clinically isolated 
syndrome (CIS) only a single MRI demonstrating DIS, gadolinium enhancing and non- 
enhancing lesions are enough for determining whether the patient has clinically definite 
MS (CDMS). It also suggests that in the above-mentioned case MRI showing DIS and 
gadolinium and non-enhancing lesion can replace the earlier DIT criteria provided that 
the gadolinium enhanced lesions are not caused by something else than MS. In addition 
to that, by using the much simplified MAGNIMS criteria, the diagnosis of CIS could be 
based on just one MRI scan (Montalban et al., 2010).  It helps simplify the diagnostic 
process for the clinician without compromising on accuracy. It is also pertinent to mention 
that in case the patients don’t have gadolinium enhancing and non-enhancing lesions in 
conjunction, DIT criteria must be applied for diagnosis.  
 
Although not in routine clinical use, it is also now possible to distinguish between active, 
chronic and slowly expanding lesions by analyzing paramagnetic rims on MRI. Also, 
longitudinal MTR maybe used to assess the demyelination or remyelination in a patient 
which contributes significantly to neurodegeneration (Absinta et al., 2016a; b). 
 
CSF examination helps to confirm the inflammatory nature of the white matter focal 
lesions. CSF findings are considered to be compatible with neuroinflammation if there is 
an increase in IgG or presence of oligoclonal bands on CSF electrophoresis and 
mononuclear pleocytosis. A negative CSF finding in terms of neuroinflammation might 
suggest that the white matter lesions are caused by other etiology, such as ischemia.  
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2.2 Parkinson’s disease 
 
Parkinson’s disease is a progressive neurodegenerative disorder. It is believed that it 
affects almost 1% percent of the population above the age of 65 years (Lang and Lozano, 
1998a; b). In Finland, according to case-finding studies, the current prevalence of PD is 
approximately 300/100,000 (Ylikotila et al., 2015).  
 
2.2.1 Pathogenesis of Parkinson’s disease 
 
PD is a multifactorial disease (Figure 1). All the cardinal clinical manifestations of PD 
occur primarily because of loss of dopaminergic neurons in the brain. The principle area 
affected is the substantia nigra pars compacta (SNc), a basal ganglia structure located in 
the midbrain. It is now believed that at the time of first clinical symptoms, there already 
is a widespread pathology resulting from various different mechanisms before the 
involvement of SNc, which occurs somewhere in the later stages of PD (Braak et al., 
2003). The cardinal pathological feature of Parkinson’s is considered to be the presence 
of Lewy bodies (LBs) in the surviving neurons (Wakabayashi et al., 2007; Shults, 2006). 
In addition to LBs, Lewy neurites are also found in the surviving structures of the brain.  
PD has long been considered as an idiopathic disorder of the brain. Recent advances in 
genetic and epidemiological studies have provided an alternative view to the long held 
notion that PD is primarily a non-genetic disorder of the brain. Newer studies suggest that 
Parkinson’s, indeed, has a genetic component to its pathophysiological mechanism 
(Dawson and Dawson, 2003; Shulman et al., 2011; Gasser, 2007; Xiromerisiou et al., 
2010).  
 
The cardinal features of PD are tremors, bradykinesia, postural instability and muscular 
rigidity. Along with these primarily motor symptoms, the disease may also have non-
motor symptoms that may include speech difficulties along with neuropsychiatric  
symptoms (Chaudhuri et al., 2005; Poewe, 2008). These non-motor symptoms along with 
others are the first to appear in a PD patient, well before the motor symptoms (Berg, 2006; 
Siderowf and Stern, 2006).  
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Figure 1 Multifactorial etiology of PD                                                                                                                                                                                 
Modified from  (Dalvi et al., 2014)          
 
Motor symptoms of PD arise from the degeneration of nigrostriatal pathway of the brain. 
Other dopaminergic pathways such as the mesocortical and mesolimbic pathways don’t 
exhibit the same kind of degeneration as nigrostriatal pathways and remain relatively 
intact. Further, there is widespread cell loss in multiple brain areas. These areas include 
locus ceruleus, ventral forebrain and raphe nucleus among others. The cell loss leads to 
an imbalance in noradrenaline, acetylcholine and serotonin in the respective areas 
(Shulman et al., 2011). Precisely how this culminates into the overall pathology of PD is 
still not clear.  
 
Although the pathological mechanism of PD is still unclear, there are certain key features 
that do give us a clue. One of them is the presence of cytoplasmic inclusions also known 
as Lewy bodies in the neurons (Wakabayashi et al., 2007). The other is microgliosis that 
indicates neuronal inflammation. This inflammation may contribute to the underlying 
pathology (McGeer and McGeer, 2008).  
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Dopaminergic loss in PD can adversely affect a number of processing loops in the brain. 
These processing loops from cortex to basal ganglia and back to cortex via thalamus are 
critical in controlling voluntary movements in an organism (Obeso et al., 2004). 
Dopamine is the major regulatory neurotransmitter in these processing loops as well as 
other pathways. This signifies the therapeutic advantage of dopamine and the reason for 
it having the central role in the current symptomatic treatment regimen for Parkinson’s 
disease.  
 
As the disease progresses, however, the treatment regimen becomes more complex 
primarily because of the chronic use of levodopa (Jankovic and Stacy, 2007). Levodopa 
starts to show the so-called ‘wearing off’ and ‘on-off’ phenomenon. This means that the 
effect of the drug wears off in a shorter duration of  time and the patient has to take higher 
doses in order to maintain the same effect (wearing off). The on/off phenomenon refers 
to the unpredictability of the drug itself as the patient oscillates between mobility and 
immobility. This phenomenon can be alleviated by adding COMT or MAO B inhibitors 
to the treatment regimen but the effect is not long lasting. 
 
Dopaminergic drugs also have acute and chronic side effects that may include vomiting, 
nausea to adverse cardiovascular as well as hormonal changes. Dopaminergic drugs may 
also show adverse neuropsychiatric symptoms such as psychosis and cognitive decline. 
Recent studies have also shown a large number of patients suffering from compulsive 
gambling and hyper sexuality. These adverse effects may be attributed to the 
dysregulation of dopamine (Dodd et al., 2005; Steeves et al., 2009; Stamey and Jankovic, 
2008; Pontieri et al., 2015; Weintraub et al., 2010; Voon and Fox, 2007). Dopamine based 
treatment also tend to increase the incidence of depression and anxiety in a large number 
of patients (Weintraub et al., 2008). 
 
It is also pertinent to mention here the interaction of A2A receptors and α-synuclein. In a 
recent study, it was shown that use of selective A2A blockers halts both IC and EC effects 
and helps reduce α-synuclein induced cellular and neuronal toxicity. In addition to that, 
A2A receptor inactivation also prevents the adverse effects of α-synuclein on synaptic 
transmission. This effect may be attributed to the regeneration of glutamatergic NMDA 
signaling due to A2A receptor blockade. Furthermore, A2A antagonism markedly decreases 
α-synuclein aggregation (Ferreira et al., 2015). This effect might explain the 
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neuroprotective effects of Adenosine A2A antagonists which are discussed in detail later 
in this thesis.  
 
As shown in Figure 1, parkin gene is the most common genetic mutation that leads to 
autosomal-recessive PD. The mutation of this gene is also responsible for initiating PD 
in adolescents (<20 years) which is termed as juvenile PD. Patients affected with this 
mutation usually suffer from a relatively earlier onset of disease with a good response to 
dopaminergic treatment (Gosal et al., 2006). Physiologically, parkin is involved in cell’s 
proteolytic pathways. Its mutation may lead to loss of mitochondrial function causing PD 
(Spratt et al., 2013; Kitada et al., 1998). Parkinson’s disease also has an infectious 
component to its etiology with anti-EBV antibodies showing cross reactivity with α-
synuclein in PD patients hypothetically thorough the process of ‘molecular mimicry’ 
(Woulfe et al., 2014). Studies show evidence of chronic inflammation in PD affected 
areas of the brain with reactive microglia despite lack of viral infection (McGeer and 
McGeer, 2004).  
 
Inflammation is also being studied as one of the cause of neurodegenerative diseases 
including PD. Microglia are one of the primary mediatory cells for inflammation in CNS. 
Their activation in SNc in particular is a strong indicator for neurotoxicity (McGeer and 
McGeer, 2008). Microglia play several roles for mediating inflammation which includes 
secretion of prostaglandins to a number of different growth factors. They also secrete 
interferons, interleukins and ROS. These substances may either play a part in 
neuroprotection or end up enhancing oxidative stress and activating apoptotic pathways. 
The resulting chronic inflammation make the SNc neurons susceptible to cell death 
(Schwab and McGeer, 2008). A number of different medications have been hypothesized 
to protect the brain against this chronic inflammation. These medications include 
Telmisartan, an ARB, and Thiazolidinediones, an oral anti Type 2 DM drug, which 
mediates their neuroprotective effect via activation of PPAR-γ (Kurihara et al., 2006; 
Saavedra, 2012; Ridder and Schwaninger, 2012). In addition to that, Pioglitazones, 
Rotenone and Isradipine (DiCCB) have also shown promising results in different animal 
models (Ulusoy et al., 2011).  
 
One more aspect of the pathogenesis of PD is oxidative stress. It’s caused by the free 
radicals produced because of oxidation of dopamine via enzymes as well as external 
toxins e.g. MPTP. This oxidative stress eventually results in PD and is one of the key 
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mechanisms that result in the causation of the disease. Oxidative stress can be traced back 
to neuronal as well as glial sources. Increased production of mitochondrial free radicals 
is considered the major contributor to oxidative stress. MPTP’s inhibition of ETC 
complex I and genetic mutation like parkin, PINK1 and DJ-1 leads to disruption in 
mitochondrial function. This suggests that both environmental and genetic factors of PD 
have a common target i.e. mitochondria for causing the disease. 
 
In conclusion, the pathogenesis of PD is extremely complex involving a lot of different 
factors using a lot of different mechanisms to inflict damage in a lot of different ways. 
No wonder it has been termed ‘enigmatic’ (Woulfe et al., 2014). 
 
2.2.2 Signs and Symptoms of PD 
 
There are four main cardinal symptoms of Parkinson’s disease including tremor, rigidity, 
akinesia and postural instability. Although these are the principle symptoms that are 
present in a PD patient, there are other motor and non-motor symptoms (Table 1) that 
may or may not be present alongside these symptoms. 
 
 Motor symptoms Non-motor symptoms 
 Tremor, bradykinesia, rigidity, postural instability 
Hypomimia, dysarthria, dysphagia 
Decreased arm swing, shuffling gait, festination 
difficulty arising from chair, turning in bed 
Micrographia, cutting food feeding 
Glabellar tap reflex, blephrospasm, dystonia, 
scoliosis, camptocormia 
Cognitive impairment, bradyphrenia, tip-of-the-
toungue 
Depression, apathy, anhedonia, fatigue, other 
behavioral and psychiatric problems 
Sensory symptoms: anosmia, ageusia, paresthesias 
Dysautonomia, weight loss 
Sleep disorders (REM behavior disorder, vivid 
dreams, daytime drowsiness, sleep fragmentation, 
RLS) 
Table 1 Parkinson's disease symptoms                        
Modified from (Jankovic, 2007) 
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2.2.3 Diagnosis of PD 
 
UK PD SOCIETY BRAIN BANK’S CLINICAL CRITERIA FOR PD DIAGNOSIS 
 Step 1 
Bradykinesia 
At least one of the following 
Rigidity 
4-6 Hz rest tremor 
Postural instability not caused by either cerebellar, vestibulocochlear, optic or proprioceptive dysfunction 
 
Step 2 
Exclude other possible causes 
 
Step 3 
Atleast 3 of the following criteria 
Tremor at rest, Unilateral onset, Progressive, Response to L-Dopa, Chorea caused by L-Dopa, L-Dopa response for 
five years +, Over all disease course of 10 years +, Persistent asymmetry mainly on the side of onset 
Table 2 Diagnostic criteria for PD                                 
Modified from (Jankovic, 2007) 
 
 
2.3 Adenosine A2A receptors 
 
Adenosine is a cyto-protective modulator that usually protects the organs or tissues 
against stress (Haskó et al., 2008). There are multiple ways by which adenosine protects 
the tissues e.g. vasodilation and resultantly increasing blood supply (Ryzhov et al., 2008), 
ischemic preconditioning (Cohen and Downey, 2008) and decreasing inflammation by 
reducing the activation as well as the infiltration of inflammatory cells (Chen et al., 2006). 
It can also reduce inflammation by decreasing both the production of cytokines as well 
as free radicals (Martin et al., 2006). Adenosine has four different receptor subtypes: A1, 
A2A, A2B and A3. In human brain, A1, A2A are the most prevalent receptor subtypes. 
 
2.3.1 Structure of A2A receptors 
82.9% base pair homology exists between the A2A receptors of humans and mice. The 
A2A encoding gene  is found on chromosome number 22 in humans (Deckert et al., 1997). 
In the 2nd intracellular loop of the A2A receptor relative to transmembrane segments 3 and 
4 lie two exons and a long intron roughly 6-7.2 kb in length (Peterfreund et al., 1996). In 
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all the tissues where A2A receptors are located they exhibit one hybridizing transcript 
(Stehle et al., 1992). It is also pertinent to mention that not only are A2A receptors 
polymorphic but also contain a silent mutation in certain populations.  This T1083C 
mutation is found to be more common in Caucasians as compared to Asians (Le et al., 
1996; Deckert et al., 1996). 
 
2.3.2 A2A receptor distribution 
 
It is important to understand the distribution of a particular receptor in order to understand 
where the agonists as well as antagonists would act if they were given to an organism. 
Higher number of receptors almost always correlates with greater efficacy of agonists 
(Kenakin, 1995). To put it in context of adenosine, because of its low quantity, it may be 
able to trigger a response where A2A receptors are abundant but won’t be able to do the 
same where receptors are low. 
 
In a normal human brain A2A receptors are primarily located in deep grey matter. They 
have the highest density in basal ganglia mainly in putamen. This number is closely 
followed by caudate nucleus and thalamus. Cerebral cortex especially frontal lobe has the 
least density of A2A receptors in a healthy human brain (Ishiwata et al., 2005; Naganawa 
et al., 2007; Sakata et al., 2017b).  
 
In patients with MS the density of A2A receptors increases in the NAWM (Rissanen et al., 
2013b). Similarly, in Parkinson’s disease the density of A2A receptors increases in caudate 
and putamen specifically in patients experiencing levodopa induced dyskinesia. No 
increase in receptor density was observed in PD patients under dopaminergic treatment 
without dyskinesia compared to healthy controls (Ramlackhansingh et al., 2011). Also 
there is an increase of adenosine A2A receptors on the lymphocytic membranes in PD 
(Casetta et al., 2014). A similar increase is also seen in patients suffering from MS 
(Vincenzi et al., 2013).  
 
Adenosine A2A receptors are also found in cardiac tissues as well as alveoli of lungs. 
Activation of A2A receptors in both organs helps suppress inflammatory cascade thus 
preserving vital function (Toufektsian, 2005; Alfaro et al., 2017). Adenosine A2A 
receptors are also present in abundance in brown adipose tissue as well as in skeletal 
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muscles in comparison to other adenosine receptors (Gnad et al., 2014; Lynge and 
Hellsten, 2000).  
 
The receptors are also present and functionally important in the GABAergic areas of the 
hippocampus, dorsal striatum and cortex (Rosin et al., 1998). Receptor density of A2A 
receptors is significantly higher in the cortex as well as hippocampus in comparison to 
other adenosine receptors e.g. A1A. In addition to dopaminergic and GABAergic, some 
studies confirm presence of A2A receptors in cholinergic neurons as well using in situ 
hybridization (Dixon et al., 1996) and PCR (Richardson et al., 2000). Other studies, 
however, suggest that there is a lack of A2A receptors in both cholinergic and/or 
GABAergic interneurons (Augood and Emson, 1994). There is no clear explanation for 
these contradictive findings. 
 
Multiple methods have been used over the years to unveil the distribution of A2A receptors 
in the body. Use of radioligands is one of the most effective of these methods. Other 
methods include using antibodies to locate A2A receptors in striatum, 
immunohistochemistry in carotid bodies, T-cells (Koshiba et al., 1999) for cardiovascular 
tissues (Marala and Mustafa, 1998; Gauda et al., 2000), angioblasts of dog’s retina 
(Taomoto et al., 2000), human GIT (Christofi et al., 2001) and nerve terminals of 
hippocampus in rodents (Rosin et al., 1998). Adenosine A2A receptors are closely 
associated to plasma membrane as well as cytoplasmic structures which shows that the 
receptor is actively trafficked within the cell. A2A receptor trafficking in the striatum is 
still not clear and needs to be studied. 
 
Age also plays a significant role as far as receptor density is concerned in different areas 
of the brain. Studies performed on the striatum of aged rats show a decrease in the over-
all numbers of A2A receptors (Cunha et al., 1995). Age may also effect the glutamatergic, 
dopaminergic and GABAergic nerve terminals and the activity of A2A receptors within 
them (Corsi et al., 1999). If we look at these findings together, we can infer that there 
maybe an imbalance between the A2A (excitatory) and A1 (inhibitory) receptor mediated 
effects with age. In stark contrast to striatum, there is an increase of A2A receptors in the 
hippocampus and a concomitant decrease in BDNF associated tropomyosin-related 
kinase receptors. This results in an increase in the hippocampal BDNF mediated synaptic 
transmission (Diogenes et al., 2007). Recent PET study, however, partially contradicts 
these findings and suggests that although there is a decrease in A1 receptors, they found 
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no significant difference in the receptor density of A2A in between younger and older 
subjects (Mishina et al., 2012). 
 
2.3.3 A2A receptor signaling 
 
Adenosine A2A receptors are G-protein coupled receptors. They have usually been 
considered to be coupled with the stimulatory type of G-proteins. Other studies show, 
however, that they may be coupled to different type of G-proteins based on their location 
in the body (Kull et al., 2000). It is predominantly coupled to the stimulatory type of G-
protein in the peripheral tissues. The number of stimulatory type of G-protein is low in 
the A2A receptor rich areas of the brain such as the striatum. Here the A2A receptors are 
mostly coupled with Golf, a different class of G-protein. Activation of G-protein coupled 
proteins by A2A receptors result in the production of cyclic AMP. It may also result in the 
mobilization of intracellular Ca2+. Inhibition of chemotaxis occurs via A2A receptor 
activation on neutrophils (Sullivan et al., 2001). Activation of adenosine A2A also result 
in a mitogenic effect in vascular endothelial cells. This effect is largely mediated by A2A 
activation of ERK1/2 (Sexl et al., 1997). Stimulatory G protein coupled adenosine A2A 
receptors are known to desensitize quickly. This effect is believed to be mediated by 
multiple mechanisms such as Thr 298 phosphorylation via receptor kinases. In addition, 
phosphorylation by cyclic AMP dependent kinase is also considered to be involved in the 
rapid desensitization of adenosine A2A receptor (Palmer and Stiles, 1997). 
 
2.3.4 A2A receptors in Parkinson’s disease 
 
As previously described, Parkinson’s disease is one of the most common age related 
neurodegenerative diseases. Dopaminergic drugs are the main stay treatment for 
Parkinson’s disease along with MAO inhibitors and COMT inhibitors. 
 
Although dopaminergic drugs are effective in providing symptomatic relief and are still 
widely used as the primary treatment in PD, they fail to stop its progression. New 
treatments are needed to stop or at least slow down the progression of this debilitating 
disease. Because of the excessive expression of A2A receptors in the basal ganglia, the 
primary site of pathology in Parkinson’s disease, A2A antagonists were considered as an 
alternate to dopaminergic drugs for the treatment of Parkinson’s (Pinna, 2014). 
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Caudate-putamen (CPu) has the highest expression of A2A receptors as compared to other 
parts of BG. Normally CPu excites striatopallidal neurons which is inhibited by 
dopamine. In PD, with lack of dopamine, there is an imbalance in these neuronal 
pathways with striatopallidal neurons getting hyper-excited because of a lack of inhibition 
from dopamine. These striatopallidal neurons have an inhibitory effect on globus pallidus 
which normally has a stimulatory effect on thalamus. 
 
 Furthermore, there is decrease in the activity of striatonigral pathway, because of lack of 
dopaminergic stimulation, which also normally excites thalamus. This decrease in the 
excitatory impulses to thalamus by both globus pallidus as well as striatonigral pathway 
because of their own inhibition due to lack of dopamine, leads to hypokinetic movements, 
a characteristic symptom of PD. This pathway is illustrated in Figure 2. 
 
This pathway helps clarify how A2A receptor antagonists work. Antagonism of these 
receptors leads to a decrease in their excitatory effect on striatopallidal neurons which in 
turn leads to a decrease of its inhibitory effect on globus pallidus. Excitation of thalamus 
and a decrease in hypokinetic movement ensues. A2A receptor antagonists bring back 
some form of balance to these pathways which is disrupted because of lack of dopamine 
(Jenner et al., 2009; Mori, 2014).  
 
 
Figure 2 Mechanism of A2A  receptors in PD                                                                                                                                             
Reprinted from Trends in Neurosciences, Vol 29, Michael A. Schwarzschild,Luigi Agnati,Kjell Fuxe,Jiang-Fan 
Chen,Micaela Morelli, Targeting adenosine A2A receptors in Parkinson’s disease, Page No. 8., Copyright (2006), 
with permission from Elsevier  
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 Synergistic action of A2A receptor antagonists and metabotropic glutamate subtype 5 
(mGlu5) antagonists has also been reported to improve motor symptoms in PD (Kachroo 
et al., 2005; Coccurello et al., 2004). A2A-mGlu5 heteromers have also been recently 
identified in caudate-putamen. This further solidifies the importance of A2A-mGlu5 
antagonists in the treatment of Parkinson’s disease in future.  
 
There are several xanthine and non-xanthine derivatives that are currently under clinical 
trials (Table 3) for use in treatment for Parkinson’s. There are several other drugs apart 
from the ones already mentioned in Table 3 that are in different stages of development.  
 
Istradefylline (NOURIAST®), a xanthine derivative, is the only drug among the multitude 
of drugs mentioned in Table 3 that has been approved for manufacturing and clinical use, 
mainly in Japan. It has proven to improve the ‘wearing off’ phenomena when given as an 
adjunctive therapy alongside L-DOPA containing drugs in various clinical drug trials . 
The drug is manufactured as 20 mg tablets and must be taken as a single tablet daily 
alongside L-DOPA. If symptoms persist, however, the daily dosage could be doubled 
(Kyowa Hakko Kirin Co., 2013). In various clinical studies, Istradefylline was shown to 
have relatively good tolerability and safety profile. The most common adverse effects 
noted with Istradefylline therapy were nausea, dizziness and insomnia along with a 
possible worsening of dyskinesia. Some patients in the clinical trials also complained of 
other adverse effects such as headaches and hallucinations. No differences in baseline 
cardiac and blood chemistry values were noticed among treatment and control groups 
(LeWitt et al., 2008; Mizuno and Kondo, 2013; Pourcher et al., 2012; Kondo and Mizuno, 
2012; Kyowa Hakko Kirin Co., 2013).  In one of the clinical trials it was found that the 
incidence of somnolence, a common adverse effect in patients undergoing treatment for 
PD with dopaminergic drugs, lowered when patients were treated with high dose of 
Istradefylline as compared to controls and low dose treatment (Pourcher et al., 2012). 
This finding is consistent with previous studies which describe the role of A2A based drugs 
on sleep (Ferré et al., 2007).  
 
Studies have consistently shown the positive benefits of using A2A antagonists alongside 
L-DOPA based treatments for PD. They have been consistent in reducing ‘off-time’ by 
almost one hour per day in patients with advanced Parkinson’s disease. The current 
treatments e.g. MAO-B inhibitor, rasagiline and  COMT inhibitor entacapone, however, 
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show similar kind of results when used adjunctively with levodopa. It should also be 
noted that in all of the clinical trials A2A antagonists were used alongside drugs such as 
MAO-B inhibitors and COMT inhibitors so it is hard to attribute the benefits to the use 
of A2A antagonists alone. The effects of A2A antagonists without co-treatment of non-
dopaminergic PD treatments must be studied in order to correctly determine the positive 
effects of these drugs. One more factor that needs to be closely examined is the 
consumption of coffee and other caffeinated beverages in the study subjects, since 
caffeine is a non-selective adenosine receptor antagonist. At normal consumption levels, 
coffee interacts with striatal A2A receptors to the same extent as drugs specific to A2A 
receptors. Therefore, it can be concluded that caffeine consumption might interfere with 
co-administered A2A antagonists. 
 
 
Drug Company Phase 
ISTRADEFYLLINE  Kyowa Hakko Kirin Co. Ltd Approved (JAPAN) 
PBF-509 Palo-Biofarma S.L. Phase I 
ST1535, ST4206 Sigma-Tau Phase I 
TOZADENANT Accorda Pharmaceuticals Phase III (HALTED) 
V81444 (Now CPI-444) Vernalis PLC  Phase II 
Table 3 Names, associated companies and development phase of A2A receptor drugs in clinical trials.               
Table modified from (Pinna, 2014) 
 
As previously mentioned, the current treatment regimen for Parkinson’s disease does 
little to stop the neuronal degeneration, specifically of the dopaminergic neurons, which 
is the pathological basis of PD. Recent studies emphasize that blocking A2A receptors may 
help stop this neuronal degeneration (Chen et al., 2007). Although the neuroprotective 
effects of A2A antagonists have been observed in animal models, the exact mechanism 
with which these effects manifest in humans is yet to be ascertained and needs further 
investigation. In addition to lack of neuroprotective effects, the current treatment also has 
no effect on cognitive decline. This includes memory deficits experienced by patients 
relatively early in the disease as well as overt dementia in the later stage. L-DOPA has 
little to no effect on cognitive decline in PD. A2A antagonists, however, have shown 
promising results in countering cognitive decline in animal models. A2A antagonists work 
to improve cognitive function either by deleting the A2A receptor gene or by inhibiting 
their signaling (Gimenez-Llort et al., 2007). Some studies also suggest that A2A 
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antagonists may have a positive effect on reward centers of the brain in addition to areas 
of executive function (Takahashi et al., 2008).  
 
2.3.5 A2A receptors in Multiple Sclerosis 
 
As previously described, multiple sclerosis is a chronic inflammatory disease which 
primarily effects the central nervous system. It is characterized by scattered plagues of 
demyelination alongside neuronal damage and gliosis (Dutta and Trapp, 2007). Increased 
levels of adenosine in cerebrospinal fluid has been found in patients with multiple 
sclerosis (Tumani et al., 2009; Lazzarino et al., 2010). A2A receptors are found in immune 
as well as neuronal cells in the central nervous system. However, it still remains to be 
confirmed whether the activation or blockade of A2A receptors would lead to protection 
against MS. In EAE, a model to study multiple sclerosis in animals, administration of A2A 
antagonist leads to a relatively milder course for experimental autoimmune encephalitis. 
Genetic deletion of CD73, which is known to produce adenosine, yielded similar results 
(Mills et al., 2008). Subsequent studies, however, showed that loss of A2A receptors, lead 
to an exacerbation of the disease (Yao et al., 2012).  
 
Increased expression of A2A has also been noted in the peripheral lymphocytes in patients 
with multiple sclerosis. Stimulation of these receptors may lead to a marked reduction of 
pro-inflammatory substances such as TNF-α, IFN-γ and others (Airas et al., 2007; 
Vincenzi et al., 2013).  
 
Recent study shows that the role played by A2A receptor depends on the stage of the 
disease. In early stages, it protects against MS by providing an anti-inflammatory 
response specifically on T-cells. In stark contrast to its role in the earlier stage, A2A 
receptor activation may lead to tissue damage within the confines of the inflamed central 
nervous system in the later stage of the disease, according to a study conducted on the 
EAE model (Ingwersen et al., 2016). This finding must be taken into account while 
developing novel MS treatments based on A2A receptors as has been suggested in previous 
studies (Du and Xie, 2012). Apart from using A2A receptors as target for new therapies in 
multiple sclerosis and Parkinson’s disease, it can also be used to study pathological 
mechanisms in vivo. 
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2.3.6 Radiotracers for A2A receptors  
 
 [11C]TMSX [7-methyl-11C]-(E)-8-(3,4,5-Trimethoxystyryl)-1,3,7-trimethylxanthine is 
one of the most commonly used radiotracer used to visualize A2A receptors to date. Apart 
from [11C]TMSX, there are multiple other radiotracers used to target A2A receptors, 
important of them will be described here. A2A receptor radiotracers could mainly be 
categorized into xanthine and non-xanthine derivatives.  Amongst the earliest xanthine 
derivatives are 3,7-dimethyl-1-propylxanthine (DMPX) and (E)-8-(3,4-
dimethoxystyryl)-1,3-dipropyl-7-methylxanthine (KF17837) which were used for 
neurophysiological and pharmacological studies for A2A receptors. The important non-
xanthine derivative is [11C]SCH442416 which was made via O-[11C]methylation using 
SCH442416 with its 4-mthoxyphenylpropyl group. 
 
 [11C]TMSX has been found to be more stable than [11C]SCH442416 and [11C]KW6002 
in human plasma. Dynamic PET scans carried out on monkeys showed that striatal uptake 
was 10 times higher and clearance was faster when compared with [11C]KF17837.  
[11C]SCH442416 showed better CNS kinetics which is useful for better quantification 
and evaluation of ligand-receptor binding. [11C]TMSX, however, was found to represent 
CNS kinetics better when compared with [11C]KF21213. In addition to the PD studies 
reviewed earlier, other human in vivo studies using [11C]TMSX, it has been found that 
there was an increase in the receptor density in heart and skeletal muscles in males who 
were endurance trained compared with controls. In another recent study with [11C]TMSX 
it was noted that the correlation between EDSS scale and MS lesion load with A2A 
receptor binding in NAWM in SPMS patients was better when compared to the ‘gold 
standard’ magnetic resonance imaging parameters (Rissanen et al., 2013b).  
 
Recently, fluorinated analogs of SCH442416 and [11C]preladenant were evaluated as PET 
ligands in rat brains with both of them demonstrating fast tracer kinetics but the latter 
showing better A2A quantification (Khanapur et al., 2017; Zhou et al., 2017). In another 
study, [11C]preladenant was also shown to be safe in human subjects (Sakata et al., 
2017a). 18F-MNI-444 has shown the most promising results compared with all the 
radiotracers that have undergone human trials with high BPND values in areas rich with 
A2A receptors along with exceptionally good brain penetration  (Barret et al., 2015). 
 
 
  22 
2.4 Imaging modalities 
 
2.4.1 Positron Emission Tomography (PET) 
 
PET has been an important clinical and research tool since almost two decades. PET 
scanner detects the signal originating from the decay of unstable neutron deficient 
radioisotopes. This nuclear decay results in the emission of a positron, a particle that 
shares the same mass as an electron but has a positive charge on it. The emitted positron 
subsequently collides with a free electron resulting in annihilation creating two photons 
at the same time. The two photons are 180˚ apart and each carries an energy of around 
511 keV which are detected by the PET scanner, a process termed coincidence logic. 
 
A PET scanner mainly consists of a two detector system with a ring of detectors lying 
opposite to each other (Figure 3). This formation allows the PET scanner to form 
coincidences with another detector pair lying directly opposite in the ring of detectors. 
PET scanner also uses electronic collimation for the localization of events which is the 
primary reason for the high sensitivity of PET imaging.  
 
 
 
Figure 3: PET scanner ring of detectors and coincidence events                     
Reprinted from (Maher, 2006) 
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 Coincidence logic or the detected photons can be mainly divided into three groups i.e. a 
true signal, a scatter background signal and a random background signal. In an ideal 
setting, two separate coincidences cannot overlap in time and the photons would not 
scatter within the body. Coincidences that meet these criteria are considered as a true 
signal. If the emitting photons undergo Compton scatter, they are known as a scattered 
background signal. Also, if the photons are detected close in time, they are known as a 
random background signal. These background signals reduce the overall quality and 
contrast of the PET scan. To counter these random and scattered events the detector gets 
rid of the signal whose energy is not equal to 511 keV and which lacks an overlapping or 
simultaneous time stamp. A coincidence or signal with perfect energy and time resolution 
is identified as a true signal. 
 
A PET scanner is also able to locate the event relative to the mid-point between the two 
adjacent detectors also known as time-of-flight PET. It can be described by the following 
equation where the time difference (∆t) in between the detection times of two photons 
can be related to the origin of annihilation (∆𝑥) relative to, as described earlier, the mid-
point between two adjacent detectors. 𝑐 refers to the speed of light in the equation. 
 
∆𝑥 = (∆𝑡 ×  𝑐)/2 
 
Image reconstruction would not be necessary because all the coincidence events could be 
localized in three-dimensional space, provided a perfect timing resolution is attained. 
Now a days, PET scanners have a timing resolution of ~375 to 600 ps. A timing resolution 
of ~30 ps would be needed to form the image directly without using reconstruction.  
 
2.4.2 Magnetic Resonance Imaging (MRI) 
 
Magnetic Resonance Imaging or MRI is an important clinical tool for non-invasive 
visualization of soft tissues, spinal cord and brain. It mainly involves the imaging of 
spinning hydrogen nucleus which is present in water, lipid and protein containing tissues. 
The nucleus of hydrogen atom has a small magnetic field because it is continuously 
spinning and has a positive charge. If placed under a magnetic field, it aligns itself in two 
different directions, in stark contrast to a normal compass needle. They are either arranged 
with or against the direction of the magnetic field (Figure 4). To put it simply, when RF 
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energy with Larmor frequency is applied to the protons, the ones aligned with the 
direction of the field, absorb this energy and switch their direction in the opposite way. 
After releasing this absorbed energy, the protons once again return to their original 
position. This ‘turning back’ or ‘relaxation’ is primarily ascertained by the T1 and T2 
relaxation times which mainly depends on the physical and chemical composition of that 
particular tissue (Stanisz et al., 2005; Bottomley et al., 1987).  During this relaxation 
phase, a tiny amount of voltage is produced by the protons in the body coil of the MRI 
machine. This voltage is referred to as the ‘magnetic resonance signal’. In order to 
increase the image quality, a specialized local coil is used over the area of body to be 
scanned e.g. knee or spine. The main reason behind the increased contrast of MRI as 
compared to CT is because of the immense variation in T1 and T2 values. The variation 
in these values is much greater than those in tissue density. 
 
An MR image is basically a visualization of signal intensities which are demonstrated by 
bright or dark points on the image. These points in turn depend on pulse sequence, the 
strength of magnetic field, blood flow, T1, T2 relaxation times and a couple of other 
factors. Images produced can either be T1, T2 or proton density weighted. This mainly 
depends on the pulse sequence as well as the repetition and echo time that is chosen.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: (LEFT) Protons randomly arranged in the absence of magnetic field. (RIGHT) In the presence of field 
protons are aligned towards and against the magnetic field because of the difference of energy state of these 
protons (E) RF frequency flips these protons into higher state of energy which also reverses their alignment. 
Modified from (Edelman, 1993) 
 
RF  
B0  
∆E  
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Tissues with lots of free mobile water appear bright on T2 images and dark on T1 images. 
The same is true for fluids like urine and CSF although they look less dark with proton 
weighted images. To get an accurate diagnosis, all three types of images are taken to 
properly distinguish between normal and abnormal tissue e.g. in MS periventricular 
plaques can be distinguished from ventricular CSF with proton- density weighted images 
when compared with T2 weighted images.  
 
2.5 Compartmental/Kinetic modeling for PET tracer kinetics 
 
As previously stated, PET allows us to trace radiotracers injected into a patient’s blood 
with very high sensitivity. PET is being used extensively for example for detecting 
different cancers and following therapeutic response in cancer patients using 18F-
flurodeoxyglucose (18F-FDG). 18F-FDG has the tendency to accumulate in cancer cells 
because of their high metabolic demand. The resulting scan is then visually interpreted 
by the nuclear medicine specialist to determine whether the diagnosis is correct or if the 
patient is responding to the therapy. PET data, however, can be quantified for better 
diagnostic accuracy, for better evaluation of treatment efficacy and drug development. 
Although not used in routine clinical setting, compartmental model is one of the most 
common mathematical models that is used for quantificating PET data in research settings 
and for evaluating simplified quantification methods suitable for clinical use.  
 
2.5.1 Basic concepts 
 
A normal PET study starts after the administration of a radiopharmaceutical or 
radiotracer. The radiotracer itself does not indulge or interfere with normal physiological 
processes in the tissue under study.  
 
Another assumption that needs to be taken into account is that the behavior of PET tracer 
mirrors the behavior of the receptor under study and represents its properties. Brain PET 
studies are an exception to this general rule.  
 
Standardized uptake value (SUV) is the most common semi-quantitative value used for 
quantitating the distribution of a radioligand in a PET study (Keyes, 1995; Visser et al., 
2010). It is often expressed as tissue concentration (g/ml) and can be defined with the 
help of a mathematical equation where TAC is the time activity curve (tissue radioactivity 
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concentration as a function of time; kBq/ml) measured in PET image divided by the 
injected dose of the radiotracer (MBq) and weight of the patient (kg). 
 
𝑆𝑈𝑉 =
𝑇𝐴𝐶
𝐷𝑜𝑠𝑒/𝑊𝑒𝑖𝑔ℎ𝑡
 
 
As already mentioned, PET scanner detects photons emitted from the radiotracer 
regardless of their origin. These photons might be emitted from an unbound tracer, 
tracer’s metabolites or from the tracer that is bound to a protein instead of its designated 
target.  
 
To make sense of this abundance of signal, temporal information is needed for the tracer 
under study. This temporal information can only be acquired from a dynamic PET image 
in the form of a TAC or time-activity curve.  
 
To acquire this TAC, input function is needed which can be taken from the arterial blood 
after tracer injection via repeated blood sampling at specific intervals. Input function can 
also be taken directly from the PET image or can be derived from previous population-
based input data. 
 
 Compartmental model has some variables or parameters that directly correlate with 
physiological information (Watabe et al., 2006). In order to get this meaningful 
physiological or biochemical information one must fit the acquired TAC to a proper type 
of compartmental model which depends on the type of study being performed. 
 
2.5.2 Types of compartmental models 
 
There are three main types of compartmental models (CM) i.e. one tissue CM (Figure 5), 
two tissue CM and three tissue CM. Each compartment has a designated box. This box 
represents a pool of equally distributed tracer. Within the box, there are compartments 
which represent different anatomical pools within the body. The tracer moves in-between 
these compartments with first-order rate constant which is directly correlated to the tracer 
concentration within the compartment. 
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Figure 5: One-tissue compartmental model (1TCM)                       
Modified from (Anderson, 1983a) 
 
One-tissue compartmental model (Figure 5) is the simplest of all compartmental 
models. It can be described using the following equation (2.1) where C(t) [Bq/mL] is 
the total time of the radiotracer in tissue as measured by positron emission tomography. 
A(t) represents input function with respect to time t [min]. K1 (mL/cm3/min] represents 
the rate constant i.e. blood to tissue while k2 [l/min] represents the opposite i.e. tissue to 
blood. It should also be noted that K1 is capitalized in order to differentiate it from rate 
constants with different units i.e. [l/min]. K1 is a unit of volume of plasma or blood (mL) 
per volume of tissue (cm3) per min.  
 
 
𝑑𝐶(𝑡)
𝑑𝑡
= 𝐾1𝐴(𝑡) − 𝑘2𝐶(𝑡)                                                              (2.1)        
 
 
One tissue compartmental model is mainly used for blood flow quantification with tracers 
that can diffuse freely. Commonly used tracers include [15O]H2O and [18F]fluoromethane.  
 
 
 
 
 
 
 
K1 
K2 
A(t) C(t) 
  28 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 6: Two tissue comparmental model (2TCM)                       
Modified from (Anderson, 1983a) 
 
 Two tissue compartmental model has two compartments, as the name implies. The first 
one is usually referred to as the ‘free compartment’ while the second one as ‘binding 
compartment’. Two differential equations (2.2 & 2.3) are needed for two compartmental 
model (Figure 6) for the calculation of concentration curves. 
 
 In these equations time activity curves are denoted as F(t) [Bq/ml] for the ‘free 
compartment’ and B(t) [Bq/mL] for the binding compartment. T2CM can be used for 
kinetic modeling of glucose phosphorylation and uptake in 18F-FDG based models.  
 
 
𝑑𝐹(𝑡)
𝑑𝑡
= 𝐾1𝐴(𝑡) − (𝑘2 + 𝑘3)𝐹(𝑡) + 𝑘4𝐵(𝑡)                              (2.2)        
 
 
𝑑𝐵(𝑡)
𝑑𝑡
= 𝑘3𝐹(𝑡) − 𝑘4𝐵(𝑡)                                                                (2.3)        
 
 
 
 
 
 
 
C(t) 
K3 
K4 K2 
F(t) B(t) A(t) 
K1 
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Figure 7: Three tissue compartment model (3TCM)       
Modified from (Anderson, 1983b) 
 
 The 3TCM model (Figure 7), as the name implies, contains three compartments in the 
tissue. Time activity curves in these three compartments are F(t) [Bq/mL], B(t) [Bq/mL] 
and N(t) [Bq/mL] for the so-called ‘free’, ‘specific binding’ and ‘non-specific binding’ 
compartments respectively. Following equations (2.4, 2.5 & 2.6) are needed for 3TCM: 
 
 
𝑑𝐹(𝑡)
𝑑𝑡
= 𝐾1𝐴(𝑡) − (𝑘2 + 𝑘3 + 𝑘5)𝐹(𝑡) + 𝑘4𝐵(𝑡) + 𝑘6𝑁(𝑡)     (2.4)        
 
𝑑𝐵(𝑡)
𝑑𝑡
= 𝑘3𝐹(𝑡) − 𝑘4𝐵(𝑡)                                                                  (2.5)        
 
𝑑𝑁(𝑡)
𝑑𝑡
= 𝑘5𝐹(𝑡) − 𝑘6𝑁(𝑡)                                                                  (2.5)        
 
C(t) 
K3 
K4 K2 
F(t) B(t) A(t) 
K1 
K5 K6 
N(t) 
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The three-tissue compartmental model is mainly used for brain receptor based studies. It 
is also important to note that the 3TC could also lie in series to one another. Therefore, it 
is necessary to specify the equations being used and the structure of the model in addition 
to the number of compartments.  
 
2.5.3 Time activity curve (TAC) and Input function 
 
Analysis of PET tracers requires the critical information of time activity curve as well as 
input function (Figure 8). TAC can be acquired by two main methods i.e. ROI based 
method and the voxel based method. In a nutshell, ROI based method involves defining 
a region of interest and then getting an average value of that particular region of interest 
(ROI).  In the voxel based method, the time activity curve is taken pixel by pixel (voxel) 
resulting in a parametric image. Advantage of ROI based method is that it typically has 
less over all noise although it is more time consuming when done manually.  
 
 
Figure 8: Schematic diagram of a typical PET study 
 
Input function or delivery function is typically described as the total concentration of 
radioactivity of the intact (non-metabolized) radiotracer within the arterial plasma as a 
function of time. This information can be obtained by the invasive method of arterial 
cannulation. The method itself is not dangerous but it requires expertise. It also 
discourages patients and normal subjects to enroll in PET studies and exposes the 
researchers to unwarranted radiation. There are two non-invasive methods of acquiring 
input function i.e. population based input function (PBIF) and the image derived input 
function (IDIF). In PBIF, an average is taken of arterial input functions of previous 
patients and healthy volunteers and then used as input function (Eberl et al., 1997). IDIF 
is explained in detail in the following section. 
 
 
Input function
Mathematical  
model
TAC from PET
Parameters of 
interest
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2.6 Image derived input function 
 
Image derived input function has been used variedly in studies that involve the use of 
large blood vessels such as the aorta or femoral arteries with much success.  In brain 
studies, carotid artery is used primarily for ROI delineation. The results of brain IDIF 
studies have been slightly dismal because of the small caliber of carotid arteries and the 
presence of partial volume effects. 
 
2.6.1 Salient features of a typical IDIF study 
 
Multiple methods have been developed to calculate image-derived input function. In 
essence, there are three important steps that are common to all methods: (1) carotid ROI 
drawing which can be done by using co-registered MRI images or segmenting the carotids 
directly on the PET images. (2) Partial volume effects correction which is then used for 
whole blood TAC calculation. (3) Distinction of parent radiotracer from its metabolites 
by metabolite correction. This third step requires adequate knowledge of the dynamics of 
the radiotracer via blood samples as the PET scanner cannot distinguish between the 
original tracer, its metabolites and the resulting photons emitted (Zanotti-Fregonara et al., 
2011a). 
 
2.6.2 ICA ROI delineation 
 
Apart from some studies that employ different methodologies to extract time activity 
curves e.g. Independent component analysis algorithm (Naganawa et al., 2005b), cluster 
analysis (Guo et al., 2007), multiple linear regression analysis (Fang et al., 2004)  and 
dynamic factor analysis, IDIF estimation in brain PET studies usually requires manual or 
semiautomatic delineation of carotid artery ROI’s. This step is important in attaining raw 
blood time activity curves. ROI’s can be drawn on PET images directly or on co-
registered magnetic resonance images for better recognition of carotid artery length and 
diameter, in theory at least.  
 
2.6.3 Manual delineation of ROI on dynamic PET image  
 
For using the PET data only for ROI delineation, a fast image acquisition protocol has 
been suggested in earlier studies. In this protocol images with frame duration as short as 
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2 seconds were acquired. Immediately after tracer injection, the process of acquiring 
images was initiated which lasted a total of 60 min duration (Chen et al., 1998). Images 
acquired in between 12 to 48 seconds were summed and used for ROI delineation. Each 
of these summed images were visually observed and ROI’s were defined individually on 
left and/or right ICA where either or both were clearly visible. Subsequently, TAC’s were 
generated for each separate entity. The final step is defining a certain threshold for 
individual pixels so that the ones having intensity above that threshold could only be used 
for ROI delineation. Once the ROI is delineated it is copied to the rest of the slices which 
may be roughly 5 to 8. A tissue ROI is further defined in close proximity to the ICA ROI 
for the correction of the spillover effects. In the latest, slightly modified approach to the 
above mentioned technique, after the visual identification of slices containing ICA, a 
rectangle is drawn over each of them to generate a 3D cubical space which is then used 
for TAC calculation (Zhou et al., 2012). 
 
2.6.4 Automatic/semi-automatic delineation of ROI on dynamic PET image 
 
In a study evaluating automated IDIF method for dynamic PET images in HRRT scanner, 
ROI’s were delineated on frames that are summed early on (15 to 45 sec post injection) 
because ICA is visually distinguishable in them. ROI’s are delineated on 11 planes 
starting 3 planes below the circle of willis This area corresponds to the region of ICA that 
is outside the skull. The selection of this area for ROI delineation helps in countering the 
spill in effects. There are three automatic methods which can be employed for ROI 
delineation all of which relate to the threshold of the individual pixels. This threshold 
could either be defined based on the percentage of the maximum pixel value (Method 
A1), number of hottest pixels in a volume (Method A2) or number of hottest pixels per 
plane (Method A3) (Mourik et al., 2008b).  
 
An alternative semi-automatic simplified seeded reference region growing method was 
also investigated where only a single seed for each carotid artery was taken. The 
algorithm then investigates the threshold of the surrounding seeds automatically and if 
they pass the pre-defined threshold criteria, it adds them to the original seed till there are 
no more pixels to add. It should be noted however that results for both the automatic and 
semi-automatic methods defined in this study were not found to be consistent with the 
gold standard i.e. arterial input function except the automatic method A3 (four hottest 
pixels per plane) (Mourik et al., 2008b).  
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2.6.5 Delineation of ROI on dynamic PET co-registered with MRI 
 
Methods that use PET image singularly for ROI delineation are often difficult to 
undertake because of low signal to noise ratio (Fung et al., 2009). In order to resolve this 
problem, an alternative approach of delineating ROIs on co-registered MR image was 
taken in some studies (Litton, 1997). In this method, ROIs were delineated as circles 
around the carotid arteries in the region where they don’t bend both for the left and right 
ICA. An alternative approach is to put bounding boxes approx. 8cm (sagittal) x 4 cm 
(coronal) x 1.5 cm (transverse) axis. These bounding boxes were placed between the 
bifurcation of the external carotid and petrous segment of the internal carotid artery. 
Specific voxels are delineated by using different algorithms and TAC’s are measured 
based on that delineation.  
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3 AIMS OF THE STUDY 
 
The general aim of this study was to investigate whether the non-invasive method of 
acquiring input function i.e. image derived input function is reliable in comparison with 
arterial input function and population based input function for the analysis of [11C]TMSX 
radioligand. The specific aims of this study are as follows: 
 
 
I     To determine which one of the two blood pools used for ROI delineation i.e. 
ICA or VS has better correlation with arterial input function. 
II   To investigate if there are any group (MS, PD, healthy controls (HC)) and sub-
group (SPMS, RRMS, early stage PD (PDEA) and later stage PD without 
dyskinesia (PDLN)) differences in IDIF AUC’s as compared with PBIF. 
III   To investigate if there are any age-related differences in IDIF AUC’s in all 
pooled cases, pooled MS, pooled controls, and pooled PD cases. 
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4 MATERIALS AND METHODS 
 
4.1 Study population 
 
The [11C]TMSX imaging data along with arterial input data have a been collected in  
previous studies conducted at Turku PET Centre (Imaging CNS adenosine receptor 
expression in patients with multiple sclerosis, Huntington’s disease and Parkinson’s 
disease using positron emission tomography (PET) (CADEPET)) and partly reported in 
earlier studies (Rissanen et al., 2013a, 2015). A combined total of 45 study subjects 
(Figure 10) were enrolled in the study. The MS and PD patients were enrolled from the 
outpatient polyclinic of the Division of Clinical Neurosciences of the Turku University 
Hospital. 17 patients had multiple sclerosis (MS) with 8 having relapsing remitting 
(RRMS) subtype of the MS and the rest with secondary progressive disease (SPMS). 19 
patients with Parkinson’s disease were enrolled for the study with 9 in the early stage of 
the disease (PDEA, disease duration of < 2 years) while the remaining 10 in the later stage 
of the disease but (disease duration of > 5 years) without dyskinesia (PDLN).  
 
  
Figure 9: Study subject flow chart. SPMS= secondary progressive MS, RRMS= relapsing remitting MS, PD= 
Parkinson's disease, PDEA= Early stage PD, PDLN= Late stage non-dyskinetic PD, HC= healthy controls, 
OAIF=original artereial input function data 
 
For comparison, imaging data was available from 9 healthy controls. Arterial input data 
was available for 30 of the total 45 study subjects (Figure 9). All the study participants 
were aged between 18 to 75 years. Pre-requisite for controls was that they had no previous 
history of neurological disease or symptoms. MS and PD patients were enrolled according 
Total   
n=45
MS      
n=17
SPMS    
n=9
SPMS OAIF 
n=8
RRMS    
n=8
RRMS OAIF 
n=4
PD       
n=19
PDEA    
n=9
PDEA OAIF 
n=6
PDLN   
n=10
PDLN OAIF 
n=5
HC
n=9
HC         
n=9
HC OAIF    
n=7
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to the inclusion and exclusion criteria reported in earlier publications (Rissanen et al. 
2013 and 2015). Medical history was taken from all study subjects on their first visit. 
Subjects also underwent clinical cardiovascular and neurological examination. Before 
entering the study, all participants provided their written, informed consent according to 
the principles of the Declaration of Helsinki. The CADEPET study has been approved by 
the Ethical Committee of the Southwestern Hospital District. 
 
4.2 [11C]TMSX Radioligand Production 
 
[11C]TMSX radioligand was synthesized locally at Turku PET Centre’s radiochemistry 
department by using methods that have been described in detail by previous studies 
(Kawamura and Ishiwata, 2004).  
 
4.3 PET and MR Image Acquisition 
 
Dynamic PET imaging of all the study subjects were carried out at Turku PET Centre 
using ECAT HRRT scanner, the spatial resolution of which is approximately 2.5 mm in 
radial and axial directions. The field of view is usually 10 cm which covers almost all of 
the brain ending at the level of foramen magnum (de Jong et al., 2007). Study subjects 
were advised to avoid consumption of caffeine 24 hours before the scan because of the 
non-selective adenosine receptor antagonist properties of caffeine. An individually 
shaped thermoplastic face mask was used to restrict head movement during the scan. In 
addition, a motion detection device was used to record head movements. In the start, a 
transmission scan was carried out using a 137Cs point source which lasted about 6 minutes 
and was used for attenuation correction. This was followed by a dynamic emission scan 
lasting 60 minutes with 27 timed frames (6 × 10, 1 × 30, 5 × 60, 5 × 150, and 8 × 300 
seconds; total 3600 seconds). A bolus of [11C]TMSX radiotracer was injected 
intravenously and initiated at simultaneously with the initiation of the dynamic imaging. 
An automatic arterial sampling collection system was used for taking blood samples in 
the initial 300 seconds of the scan which was followed by manual arterial blood sampling 
at 5, 10, 15, 20, 30, 40, 50 and 60 minutes. In order to calculate original arterial input 
function, total radioactivity concentration along with the fraction of intact radiotracer was 
calculated from arterial blood samples taken during the scan. In addition to that, plasma 
radioactivity was calculated by multiplying the total radioactivity concentration with the 
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mean hematocrit value (0.4). Finally, using the resulting parameters, an in house 
developed software was used to calculate arterial plasma input as a function of time.  
MRI was performed using 1.5 T Nova Dual scanner. Axial T1 and T2, coronal FLAIR, 
and 3DT1 weighted in addition to DTI sequences were taken. (Rissanen et al., 2015). The 
3DTI sequence was used as anatomical reference for ROI delineation.  
 
4.4 Carotid ROI Delineation 
 
ROI’s were  delineated on summed images (frames 1-12) of the dynamic PET scan with 
co-registered MR images (Litton, 1997; Fung et al., 2009; Mourik et al., 2009). For this 
purpose, an in-house developed software Carimas 2.9 was used.  
 
 
 
Figure 10: ROI drawn (red arrow) on PET image for ICA (top left), VS (bottom left) and checked on MRI for 
correct anatomical placement for ICA  (top right and  VS (bottom right) 
ROI= region of interest, ICA= internal carotid artery, VS= transvers venous sinus, MRI= magnetic resonance 
imaging 
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Free hand tool was used to delineate ROI’s on internal carotid artery just before it joins 
the Circle of Willis (on average at the level of trans-axial slice 31 to 32). The drawn ROI 
was checked with co-registered 3DTI MR image and adjusted accordingly for better 
anatomical accuracy (Figure 10). Similar ROI’s were drawn for subsequent 5 to 8 frames 
depending on the signal intensity. In addition, ROI’s were drawn in transverse sinuses on 
dynamic PET images (on average from trans-axial slice 29 onwards for subsequent 5 to 
8 slices). This was also done with co-registered MRI for better anatomical detail making 
sure that the ROI stayed within the sinus itself. This step is necessary for the correction 
of ‘spillover’ effects of the PET signal. Finally, time activity curve (TAC) values, 
calculated within the Carimas software, were saved and used for data analysis. 
 
4.5 Data Analysis 
 
Randomized patient data including weight, height and radioligand dose administered was 
added in a spreadsheet in MS Excel. TAC’s calculated for each subject were added 
separately for internal carotid artery (ICA) and transverse venous sinus (VS). The 
following equation (3.1) was used to calculate the standardized uptake value (SUV) in 
each of the 27 frames Microsoft Excel and the SUV’s were then plotted on a graph with 
SUV on y-axis and time points on x-axis for PD and MS groups alongside controls and 
for both ICA and VS separately. 
 
𝑆𝑈𝑉 =
𝑇𝐴𝐶
𝐷𝑜𝑠𝑒/𝑊𝑒𝑖𝑔ℎ𝑡
                                                   (3.1) 
 
These SUV values for both ICA and VS were metabolite corrected. This was done by 
writing the fraction data (derived from the arterial blood samples taken during the scan) 
on an ASCII file. A ‘Hill type’ mathematical function was applied to the fraction data. 
PTAC, which is also derived from the arterial blood samples, and the fitted fraction data 
is then used to calculate metabolite corrected plasma curve using a Turku PET Center 
developed script known as metabcor. The resulting values were then plotted for individual 
cases with original input function, PBIF, individually scaled PBIF, ICA and VS SUV 
values.  
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Furthermore, using time points (t) and TAC values, area under curve (AUC) was 
calculated using the trapezoidal rule (3.2) in MS Excel. These values were plotted on a 
line graph against time points for internal carotid artery and venous sinuses respectively.  
         
𝐴𝑈𝐶 =
(𝑇𝐴𝐶𝑛 + 𝑇𝐴𝐶𝑛+1)
2
 ×  (𝑡𝑛+1 − 𝑡𝑛)                  (3.2) 
 
   IDIF values were metabolite corrected and were scaled to original input function. The 
statistical analyses were performed using SPSS (v23). Normality of data distribution was 
checked using Shapiro-Wilk test. Wilcoxon signed-rank test, a non-parametric equivalent 
of t-test, was used to evaluate possible differences between original arterial input 
function, ICAis and VSis AUC values to determine whether the IDIF method can substitute 
arterial input function. Furthermore, correlations were checked between OAIF, ICA and 
VS AUC values using Spearman’s test to determine which of the two blood pool AUC’s 
i.e. ICA or VS correlates better with OAIF. For this comparison, the ICA and VS values 
were scaled to OAIF values for each individual study subject i.e. individually scaled 
internal carotid artery input function (ICAis) and individually scaled venous sinus input 
function (VSis). 
 
Overall group differences between HC, MS and PD in the ICA AUC values were checked 
against PBIF using ANOVA with all groups pooled (HC+MS+PD). Individual paired 
comparison between HC, MS and PD were done to examine possible differences between 
groups using independent samples t-test. Subgroups (SPMS and RRMS, PDEA and 
PDLN) were checked for any significant differences using independent samples t-test.  
To calculate PBIF, Mostellar formula was used to standardize the metabolite corrected 
plasma time activity curve (Mosteller. R.D., 1987). The resulting curves were juxtaposed 
on the same time points followed by shifting them to average peak time. Lastly, they were 
normalized using the average of the group, excluding the single subject which was used 
for normalization. Individually scaled PBIF were derived from the group specific average 
using a non-invasive method incorporating body surface area and an invasive method 
using metabolite corrected arterial samples at 9 and 23 minutes which were tested to give 
the highest correlation with plasma AUC  (Rissanen et al., 2015). 
 
Finally, age related differences were investigated by dividing all the cases in two groups 
i.e. group 1 with age <45 and group 2 with age ≥45. Independent samples t-test was used 
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to check whether there were any significant differences between these two age groups. 
Spearman’s correlation was also used to check any significant correlations of age to ICA 
AUC in individual groups i.e. HC, MS and PD.  
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5 RESULTS 
 
5.1 Correlations of ICAis and VSis IDIF with original arterial input function 
 
Mean and SD values of age and the SUV AUC values acquired with original arterial 
input data, individually scaled internal carotid artery data and individually scaled 
venous arterial input data is summarized in Table 4. Healthy controls mean (sd) 49 (8.3) 
years were age matched for SPMS patients 49 (12.2) years. RRMS patients were 
significantly younger, the mean age being 27.7 (7.1) years while PD patients were older 
than the healthy controls with the mean age of [66 (8) years. When analyzing the 
differences between the methods for all pooled data IDIF with ICAis provided lower 
estimates when compared with OAIF in all groups (p= 0.004 z= -2.86). Similarly, VSis 
also provided significantly lower estimates when compared with OAIF (p= 0.000 z= -
4.86).  
 
 
STUDY 
SUBJECTS 
All 
cases 
 
(n=30) 
HC 
 
(n=7) 
MS 
(pooled) 
(n=12) 
SPMS 
 
(n=8) 
RRMS 
 
(n=4) 
PD 
(pooled) 
(n=11) 
PDEA 
 
(n=6) 
PDLN 
 
(n=5) 
AGE 52.4 
(15.3) 
49 
(8.3) 
42  
(14.8) 
49 
(12.2) 
27.7 
(7.1) 
66  
(8) 
63 
(9.5) 
69.4 
(4.7) 
OAIF 108.7 
(17.4) 
105.6 
(17.6) 
112.7 
(18.5) 
110.4 
(18.3) 
95.8 
(12.5) 
116.1 
(15.1) 
113.7 
(17.8) 
119 
(12.5) 
ICAis 98.9 
(32.1) 
103.3 
(45.3) 
106.6 
(27.5) 
104.6 
(26.1) 
100.7 
(76.8) 
98.4 
(20.6) 
94.5 
(21.1) 
103.2 
(21.4) 
VSis 64.1  
(11.4) 
64.1 
(9.1) 
61.4 
(13.1) 
63.8 
(15.1) 
56.6 
(7.0) 
69 
(8.6) 
67.4 
(8.1) 
70.8 
(9.8) 
 
Table 4 Mean (SD) of  age and AUC values (OAIF, ICAis, VSis) for all study sucjects.  
SPMS= secondary progressive MS, RRMS= relapsing remitting MS, PD= Parkinson's disease, PDEA= Early stage 
PD, PDLN= Late stage non-dyskinetic PD, HC= healthy controls, OAIF=original artereial input function data,  
ICAis= Individually scaled internal carotid artery input data, VSis= individually scaled venous sinus input data 
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Figure 11 (A) Correlation between age and area under curve (AUC) of original arterial input function (OAIF), 
individually scaled internal carotid artery (ICAis) and venous sinus (VSis) (B) Bland-Altman plot showing relative 
difference between AUC values of ICAis (relative to original input function) (C) Bland-Altman plot showing 
relative difference between AUC values of VSis (relative to original input function) 
 
There was, however, a relatively strong correlation between individually scaled ICA 
AUC (ICAis) and original arterial input function AUC values for all pooled subjects r (p)= 
R² = 0.152
R² = 0.04864
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0.792 (0.000). A relatively strong correlation was also found between the individually 
scaled VS AUC (VS is) and original arterial input function r (p)=0.686 (0.000). The 
correlations are visualized as Bland-Altman plots (Figure 11) demonstrating that ICAis 
AUC correlates better with OAIF than the VSis.  
 
In group wise analysis, strong correlation was observed in healthy controls between 
original input data and both individually scaled ICA and VS data r (p) = 0.929 (0.003). 
Also, correlation was found to be significant in MS (pooled) r (p) = 0.657* (0.015), SPMS 
r (p) = 0.728* (0.026), PD (pooled) r (p) = 0.676* (0.011), PDEA r (p) = 0.943* (0.005) 
for OI-ICAis comparison and MS (pooled) r (p) = 0.847* (0.000), SPMS r (p) = 0.820* 
(0.007), PD (pooled) r (p) = 0.648* (0.017) for VSis comparison. Results are summarized 
in Table 5. In RRMS and PDLN, no significant correlations between the methods were 
found, which could be explained by the small number of cases in these subgroups (n=4 
and n=5, respectively), and the correlation between OAIF and VSis among PDEA was 
not significant either (n=6). 
 
As the ICAis input data correlated better with the OAIF, the subsequent analyses in section 
5.2 and 5.3 were carried out using ICA AUC values as a reference. 
 
 Group OAIF-ICAis 
Spearman (p) 
OAIF-VSis 
Spearman (p) 
HC 0.929* (0.003) 0.929* (0.003) 
MS (pooled) 0.657* (0.015) 0.847* (0.000) 
SPMS 0.728* (0.026) 0.820* (0.007) 
RRMS 0.800  (0.200) 0.800  (0.200) 
PD (pooled) 0.676* (0.011) 0.648* (0.017) 
PDEA 0.943* (0.005) 0.600  (0.208) 
PDLN -0.300 (0.624) 0.700  (0.188) 
Table 5 Correlation between Original arterial input function (OAIF) and Individually scaled Internal carotid 
artery input function (ICAis) in healthy controls, MS and PD groups and subgroups. Significant correlations 
marked with asterisk (*). SPMS= secondary progressive MS, RRMS= relapsing remitting MS, PD= Parkinson's 
disease, PDEA= Early stage PD, PDLN= Late stage non-dyskinetic PD, HC= healthy controls, OAIF=original arterial 
input data, ICAis= Individually scaled internal carotid artery input data, VSis= individually scaled venous sinus 
input data 
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Although we found significant differences in between overall AUC values of IDIF and 
original arterial input function, there were similarities found when comparing SUV 
curves for individual cases (Figure 12). In figure 12A the peak of individually scaled VS 
accurately matches the peak of original plasma input function although with a faster 
descending slope and a slight under estimation of the tail.  
 
Similarly, in figure 12B individually scaled ICA and original plasma input function have 
a roughly similar peak with ICA having a faster descending slope and overestimation of 
the tail.  
 
 
 
Figure 12 Standardized uptake value (SUV) comparison between original plasma input function (Orig), population 
based input function (PBIF), individually scaled population based input function(PBIF  IS),individually scaled 
internal carotid artery input function (ICA IS) and individually scaled venous sinus input function (VS IS) with time 
in a healthy volunteer  (A) and SPMS patient (B) 
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5.2 Group and sub-group differences in IDIF ICA AUC’s and compared to 
PBIF 
 
 
 
Figure 13 Scatter plot of PBIF and ICA AUC values in respect to age in all pooled cases (n=45).                                          
PBIF= population based input function, ICA= internal carotid artery, AUC=area under curve 
 
 The SUV AUC values using IDIF ICA were further evaluated for all cases (with or 
without arterial input) for possible mean difference within group and sub-groups against 
individually scaled PBIF AUC. Significant differences were found for all study subjects 
in between groups and within sub-groups (p<0.05) except for all groups pooled 
(HC+PD+MS) (p=0.798). The results are summarized in Table 6. As mentioned before, 
ICA input data for all study subjects was used to check group and sub group differences 
as it correlated better with original input data as demonstrated in section 5.1. 
 
 
GROUP PBIF-ICA AUC 
Mean (SD), (p) 
All groups pooled (HC+PD+MS) 63.6 (15.9), (0.798) 
PD (pooled) 61.7 (16.8), (0.000)* 
PDEA  70.6 (15.6), (0.000)* 
PDLN 57.2 (12.0), (0.000)* 
MS (pooled) 65.1 (15.1), (0.000)* 
SPMS  71.7(15.0), (0.000)* 
RRMS 57.8 (12.1), (0.000)* 
Table 6 Group and subgroup differences in ICA AUC values. Group differences regarded statistically significant if 
p<0.05 (marked with asterisk*) 
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5.3 Age-related association in IDIF ICA AUC’s 
 There was no difference in the IDIF ICA AUC values with population based metabolite 
correction between the younger (n=15) [mean (SD) 34.07 (7.87)] and older (n=38) [63.5 
(8.58)] study subjects (p=0.940).   
 
Also, no significant age-related correlations were found in individual groups i.e. controls 
(r= -0.622, p= 0.074), PD (r= -0.017, p= 0.946) and MS (r= 0.422, p= 0.422). Negative 
trend was found between age and binding in healthy controls as demonstrated in Figure 
13 (A). Scatterplots summarize the results (Figure 14).  
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Figure 14 Age related associations in ICA AUC in (A) Healthy controls, (B) Parksinson's disease and (C) Multiple 
sclerosis. R2= linear regression value 
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6 DISCUSSION 
 
This study investigated an alternative approach of getting input function from the image 
for [11C]TMSX radioligand. Various methods of acquiring input function from the image 
have been employed for more than a decade (Zanotti-Fregonara et al., 2009). In our study 
we used the method requiring the use of a co-registered MR image for better anatomical 
accuracy and reducing partial volume effects (Litton, 1997). Image derived input 
functions were converted to plasma and metabolite correction was applied to the curves  
(Oikonen, 2016; Kropholler et al., 2005; Hahn et al., 2012; Schain et al., 2013). 
 
In our study we found that IDIF, although having a good correlation at group level, did 
not provide individually reliable estimates when compared to arterial input function and 
was not as accurate as the population derived input function method carried out for the 
same study subjects in a previous study (Rissanen et al., 2015). We used two different 
blood pools i.e. ICA and VS for ROI delineation which were then scaled individually 
with original arterial input function. We found that ICA derived input function had a 
much better correlation with original arterial input function after individual scaling. The 
inconsistency in the results could be attributed to the partial volume effect (Mourik et al., 
2008a; Hahn et al., 2012; Mourik et al., 2009) (PVE) or the spill in/out effects 
(Lammertsma and Hume, 1996). PVE has been a major challenge in accurately 
quantifying the image derived input function in previous studies as well, primarily, 
because of the small diameter of internal carotid artery (Fung et al., 2009) and the 
concurrent low spatial resolution (Naganawa et al., 2005a), high signal to noise ratio 
(Kalk et al., 2011; Naganawa et al., 2005a; Turkheimer et al., 2007) of the PET scanner. 
To counter the low spatial resolution problem, HRRT scanner was used in our study. 
Alternatively, to avoid partial volume effects altogether, ROI’s must be delineated on 
proximal internal carotid artery outside of the skull just after the bifurcation of common 
carotid artery. This is not possible with the use of HRRT scanner because it is unable to 
acquire images below the level of foramen magnum.  
 
[11C]TMSX tracer kinetics might also have played a part in the inaccuracy of our results 
primarily because of the lack of insight on how it behaves once injected into the blood 
stream. The usual assumption, when calculating IDIF, is that the tracer gives an accurate 
foreground to background ratio or in other words, has a strong carotid signal. This might 
not be the case with [11C]TMSX because it has the tendency to bind with A2A receptors 
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present in the blood vessel and/or it immediately diffuses into the surrounding tissues 
which results in weak carotid signal on which, later on, the ROI is erroneously delineated. 
Co-registration errors may also effect the quantification of IDIF (Fung et al., 2009; Litton, 
1997) primarily because of the elastic nature of carotid artery. As the ROI on carotid 
artery is delineated just below the circle of Willis, the position of the artery may vary 
between the PET and MRI. Motion detectors were used in our study to correct positioning 
of internal carotid artery and to eliminate co-registration errors but ideally hybrid PET-
MR machines should be used to completely eliminate this problem. 
 
Another aspect that needed to be investigated was the age related difference in the arterial 
input of the [11C]TMSX radiotracer. A previous study showed that there were no age 
related differences in the specific binding, measured as DVR for [11C]TMSX radiotracer 
in the striatum of healthy controls (Mishina et al., 2012). Our results were in line with the 
former study as we did not find any age-related differences in IDIF AUC values. It goes 
to show that there is no difference in the arterial input of [11C]TMSX radiotracer amongst 
different age or disease groups. 
 
Individually scaled PBIF was considered a viable substitute for original plasma input 
function in a previous study (Rissanen et al., 2015). PBIF, however, is much less sensitive 
for individual subjects as compared to original arterial input function. We found no 
differences in IDIF AUC values in comparison to PBIF in our pooled study population. 
There were, however, differences in Parkinson’s disease group which included both early 
onset and late onset PD patients. Also, differences were found in between early onset and 
late onset PD patient sub groups. Similarly, differences were found for MS patients which 
included both SPMS as well as RRMS patients as well as between SPMS and RRMS 
patient subgroups.  
 
As shown in the comparison of SUV AUC curves for original arterial input function and 
individually scaled ICA and VS curves (Figure 12) the method we used can estimate IF 
correctly in some individual cases of healthy controls and SPMS patients. In the majority 
of cases during visual analysis we found that there was an overall underestimation of the 
peaks and over estimation of tails.  
 
We can, therefore, conclude that the image derived input function method we evaluated, 
originally devised by Litton, for acquiring input function for [11C]TMSX was not as 
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accurate as original arterial input function or population based input function validated 
earlier. This, however, does not mean that input function cannot be extracted from the 
image for [11C]TMSX radiotracer as there are multiple other IF extraction methods as 
well. In an earlier study, input function was obtained for identical data using eight 
different extraction methods with only one resulting in accurate input function estimation 
(Zanotti-Fregonara et al., 2009). The results attained from the method devised by Litton 
were similar to the ones we got in our study showing underestimation of peaks and over 
estimation of tails of SUV curves (Figure 14). Taking this into account, the method 
devised by Chen (previously mentioned in section 6.3), in which only dynamic PET 
images were used to delineate the ROI seems like a viable alternative to the method we 
used in our study to derive input function. This method could be used for acquiring IDIF 
for [11C]TMSX in future studies. 
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7 CONCLUSION 
 
Although IDIF has been used extensively in previous studies for correct quantification of 
input function with different radioligands, in our study we have concluded that the method 
we used to attain it is not viable enough for [11C]TMSX radioligand. Therefore, other 
input function extraction methods for [11C]TMSX can be further investigated in future 
studies. 
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